Medical News: ECCO-ESMO: Bevacizumab Safe in 'Real World'

Action Points

---

• Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  



• Explain that a retrospective study showed a benefit for bevacizumab in patients with recurrent ovarian cancer, similar to benefits seen in prior clinical trials.
  



• Note that the greatest benefit from bevacizumab was seen in platinum-sensitive ovarian cancer and those receiving second- or third-line treatment in combination with chemotherapy.

Medical News: ECCO-ESMO: Spikes in Liver Enzymes Common in Ovarian Cancer Tx (Trabectedin / Yondelis)

Action Points

---

• Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.



• Explain that liver transaminase abnormalities in patients with advanced ovarian cancer who received trabectedin did not impact outcomes, including response rate.



• Note that liver transaminase abnormalities were seen in 63% of patients studied.

Medical News: SABCS: Removing Ovaries May Put Bone Health at Risk - in Meeting Coverage, SABCS (cancer prevention/BRCA)

Blogger's Note: note absence of Lynch Syndrome/female cancer prevention

MedPage Today Action Points

• This study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
• The removal of both ovaries, which is often done as a preventive measure in women at high risk of breast cancer, may increase a younger woman's likelihood of low bone mineral density (BMD) and arthritis.
• The prevalence of arthritis was even higher in women who had their ovaries removed before age 45.

Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients

Bioidentical hormone therapy: Clarifying the misconceptions

Copy Number Variation Analysis of Matched Ovarian Primary Tumors and Peritoneal Metastasis

Blogger's note: technical

Our study highlights the benefit and importance of performing paired analysis of primary tumors and their metastatic lesions in ovarian cancer. While comparison of primary and metastasis as groups provided insight into cancer development, the matched analysis allowed more specific detection of consistent differences. Indeed advanced disease allows access to not only the primary but also the different metastatic sites. It has been clearly demonstrated that the patients' prognosis relies on tumor residue; therefore it is critical to understand the biology of the metastatic lesions in order to design appropriate new therapeutic approaches. The results presented here should be a step in that direction.

Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection

This strategy identifies a substantial number of LS patients who would have been missed if genetic testing was based on the Amsterdam II Criteria alone.

Microsatellite Instability in Saliva from Patients with Hereditary Non-polyposis Colon Cancer (Lynch Syndrome) and Siblings Carrying Germline Mismatch Repair Gene Mutations

Saliva testing, a less-invasive procedure than PBL testing, is more sensitive and appears to be a viable alternative for identifying MSI in carriers with MMR mutations.

Two cases of ovarian metastasis of colon cancer

Ovarian tumors were diagnosed as metastasis from colon cancer. Ovarian metastasis of colon cancer is a relatively rare event, but a long-term survival case has been reported by multimodality therapy including surgery.

Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas

Patient-Reported Outcomes in Oncology - Center for Medical Technology Policy - survey feedback deadline Jan 30rh, 2012

On May 24, 2011, the project team presented their recommendations at the ISPOR16th Annual International Meeting.

The EGD is available for public comment. Click the following link to download, PRO EGD Final (35), and visit this survey by January 30, 2012 to provide feedback.

For more information, contact Merianne (Tiglao) Spencer.

link to the document - pdf file:

Recommendations for Incorporating Patient-Reported Outcomes into the Design of Clinical Trials in Adult Oncology

Clinical Care Options - Oncology CME - The Right Care for the Younger Patient: Meeting the Needs of Adolescents and Young Adults With Cancer

Blogger's Note: access is free after registering, slideshow (powerpoint) discusses genetics (eg. BRCA/Lynch Syndrome genes/implications)

Use of Complementary and Alternative Medicine by Cancer Patients at a Montreal Hospital

Conclusion:
Whereas disclosure of natural health products use is occurring, informative CAM discussion is not.

Journal of Ovarian Research | Full text | Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

Table 1. Patients characteristics.

Dec 2011: Journal of Ovarian Research Gene Expression and Pathway Analysis of Ovarian Cancer Cells Selected for Resistance to Cisplatin, Paclitaxel, or Doxorubicin

Background

Resistance to current chemotherapeutic agents is a major cause of therapy failure in ovarian cancer patients, but the exact mechanisms leading to the development of drug resistance remain unclear. 

Results

A total of 845 genes (p<0.01) were found altered in at least one drug resistance phenotype when compared to the parental, drug sensitive cell line.......

Conclusions

Ovarian cancer cells develop drug resistance through different pathways depending on the drug used in the generation of chemoresistance. A better understanding of these mechanisms may lead to the development of novel strategies to circumvent the problem of drug resistance.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Medline search: 3,495 articles found for: ALL(whole abdominal radiation ovarian cancer)

http://www.sciencedirect.com/science?_ob=ArticleListURL&_method=tag&_temp=&sort=r&sisrterm=&_ArticleListID=1869327428&view=c&_chunk=0&count=1000&_st=&refsource=&_acct=C000228598&_version=1&_urlVersion=0&_userid=10&md5=c13efc117a7aa8062a05f64363fa4bbf&searchtype=a&originPage=rslt_list

Mucinous Tumors of the Ovary: Diagnostic Challenges at Frozen Section and Clinical Implications

Conclusions

Our study showed a 34% rate of discordance between FS and final diagnosis. Given that 5 cases (7%) were of GI origin, intraoperative assessment of the appendix should be performed in all mucinous ovarian tumors.

Highlights

► We examined 73 consecutive cases of mucinous ovarian tumors that had frozen section (FS) at the time of surgery.
► The rate of discordance between FS and final diagnosis was 34%.
► Consideration of appendiceal tumors is important as 7% of all cancers were found to be gastrointestinal in origin.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Highlights

► The maximum tolerated dose and feasibility of IV and IP chemotherapy was assessed.
► The dose limiting toxicity rate for Paclitaxel 175 mg/m² IV, carboplatin AUC 6 IP and paclitaxel IP was 35%.

A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life

Objectives

Gynecological neoplastic disease progression is characterized by specific energy metabolism alterations and by symptoms including fatigue, anorexia, nausea, anemia, and immunodepression, which result in a cachexia syndrome and a marked decrease in patient quality of life (QoL). Therapeutic protocols associated with appropriate and effective psychological and social support systems are essential to counteract the symptoms of neoplastic disease in incurable patients.

Highlights

► Progression of gynecological cancers is characterized by specific alterations of energy metabolism and symptoms that impact quality of life.
► We compared a combined versus a single-agent approach for the treatment of advanced gynecological cancer-associated symptoms.
► Multimodal regimen was more effective in improving both immunometabolic alterations and quality of life in advanced gynecologic cancer patients.

Brain Metastases from Epithelial Ovarian Carcinoma: Evaluation of Prognosis and Managements - A Taiwanese Gynecologic Oncology Group (TGOG) Study

Conclusions

However, clinicians should keep alert to the neurological complaints of ovarian cancer patients and the patients might benefit from aggressive multimodal treatments.

Highlights

► The clinical characteristics of brain metastases from epithelial ovarian carcinoma.
► To identify prognostic factors and optimal treatment strategy in these patients.

ScienceDirect - Gynecologic Oncology : Proceedings from the 9th International Conference on Ovarian Cancer

Blogger's note: requires ($$$) subscription to view

Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer

blogger's note:

Table 2. Site of first recurrence.
Table 3. Pattern of first recurrence

"In conclusion, patients treated with adjuvant IP chemotherapy appear to have a different pattern of disease recurrence than patients treated with IV chemotherapy. The locations of these recurrences reflect the ability of IP chemotherapy to successfully eradicate disease within the anatomic regions of drug distribution.
Recurrent disease outside the abdominal cavity can be anticipated to occur more frequently in the current era of primary IP chemotherapy.
Further efforts should be aimed at improving IP distribution of chemotherapy to areas that may become disease sanctuaries."

Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A GOG study

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

Editorial: Advances in ovarian cancer disease control

"Overall, when one considers the relative mortality to incidence annually, ovarian cancer is the second most lethal among women in the United States. It is estimated that in 2011, there will have been 21,990 new cases diagnosed and 15,460 ovarian cancer deaths [1]. Epithelial ovarian cancers and related malignancies, most predominantly high grade serous tumors, contribute most to this public health care burden [2], and thus will be the focus here. While it is beyond the scope to recognize all recent contributions, the purpose of this editorial is to report on several key advances in disease classification, public health, treatment, detection and prevention and to place these advances in context of pre-existing knowledge......"

Editorial: Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges?

Incidence and Factors Associated with Synchronous Ovarian and Endometrial Cancer: A Population-Based Case–control Study

Carcinosarcoma of the ovary: A review of the literature

A systematic review evaluating the relationship between Progression free survival and Post Progression survival in advanced ovarian cancer

A study of symptoms described by ovarian cancer survivors

"There was a marked discordance between questionnaire-reported symptoms and those recorded in hospital notes."

Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer

Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy?

Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity